• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Metabolic Diseases
    4 Drugs classified under this therapeutic system


    All the Therapeutic System Drugs

    Kuvan
    Medison
    RX
    partial basket chart
    Kuvan

    Enzyme Cofactor. Sapropterin (dihydrochloride) 100 mg.
    SOL. TABS: 30, 120 x 100 mg. 5-20 mg/
    kg/dly. See lit.
    Tmt. HPA in adults, child over 4 yrs with
    PKU, shown respons. to such tmt. Tmt.
    HPA in adults, child over 4 yrs with BH4
    defic., shown respons. to such tmt.
    C/I: Hypersens.

    Orfadin 2 mg, 5 mg, 10 mg
    Megapharm
    RX
    partial basket chart
    Orfadin 2 mg, 5 mg, 10 mg

    4-Hydroxyphenylpyruvate Dioxygenase Inhibitor. Nitsinone 2, 5, 10 mg.
    CAPS: 60. Recomm. inititial dose in
    ped., adult populat: 1 mg/kg body wt
    dly in 2 divid. doses.
    Tmt. pts with confirmed diagnos.
    hereditary tyrosinemia type 1 (HT-1) in
    combinat. with dietary restrict. of tyrosine
    and phenylalaline.
    C/I: Hypersens., lact.

    Praluent 75, 150 mg
    Sanofi
    RX
    partial basket chart
    Praluent 75, 150 mg

    Monoclonal Antibody. Alirocumab 75 mg/ml, 150 mg/ml.
    PEN/SYR.: 1,2×75,150 mg/ml
    The usual init. dose is 75 mg admin. SC once every 2 wks.
    Pts. requir. larger LDL-C reduction (>60%) may be started on 150 mg admin.
    SC once every 2 wks.
    The dose can be individual. based on pt. characteristics such as baseline
    LDL-C level, goal of ther. &response. See lit.
    Primary Hypercholesterolaemia (heterozygous familial &non-familial) or mixed dyslipidaemia in adults, as an adjunct to diet:
    - in comb .with a statin or statin with other lipid lowering therapies in patients unable to
    reach LDL-C goals with the max. tolerated dose of a statin or,
    - alone or in comb. with other lipid-low. therapies in pts. who are statin-intoler.
    The effect of the drug on cardiovasc. morbid. and mortal. has not yet been determin.
    C/I: Hypersens.

    Repatha
    Amgen
    RX
    partial basket chart
    Repatha

    Human Monoclonal Antibody. Evolocumab 140 mg/ml.
    PRE-FILL.PEN.: 1, 2, 3, 6. Prim.
    hypercholesterolaemia & mixed
    dyslipidaemia in adults: 140 mg every
    two wks. or 420 mg once mnthly.; both
    doses are clinic.equival.
    Homozyg. fam. hypercholesterolaemia
    in adults & adolesc. aged 12 yrs. and
    over: Initial. 420 mg once monthly.
    After 12 wks. of tmt., dose frequen. can
    be up titrated to 420 mg once every 2
    wks. if a clinic. meaningful response is
    not achieved. Pts. on apheresis may
    init. tmt. with 420 mg every two wks. to
    corresp.with their apheresis schedule.
    Hypercholesterolaemia & mixed
    dyslipidaemia. Primary
    hypercholesterolaemia (heterozygous
    famil. & non famil.) or mixed
    dyslipidaemia in adult., as an adjunct to
    diet: In comb. with a statin or statin with
    other lipid low. therap. in pts. unable to
    reach LDL C goals with the max.
    tolerated dose of a statin or, Alone or in
    comb.with other lipid-low. therap. in pts.
    who are statin-intolerant/ for whom a
    statin is contraind. Homozyg. famil.
    hypercholesterolaemia in adults &
    adolesc. aged 12 yrs. and over with
    homozyg. famil. hypercholesterolaemia
    in comb. with other lipid-low. therap.. The
    effect of Evolocumab on cardiovasc.
    morbidity & mortal. has not yet been
    determined.
    C/I: Hypersens.


    Other therapeutic systems under Affecting Nutrition and Metabolism

    CLOSE